Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
With a mission to redefine what gene therapy can do, Spur is optimizing every component of its product candidates to develop a new generation of gene therapies Spur is advancing two potentially...
Freeline Therapeutics has announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine. Moving forward, the brand will be called Spur Therapeutics.
SCOTTSDALE, Ariz., May 09, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial...
Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Acquisition of Freeline by Syncona Becomes Effective
Freeline Shareholders Approve Acquisition by Syncona
Syncona to Acquire Freeline Therapeutics
After mulling a potential buyout for a month, Freeline Therapeutics has decided that its future lies in the arms of its majority shareholder.
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Con